By Ed Frankl 
 

Fresenius SE said Tuesday that second-quarter profits fell, buffeted by "significantly worsening" business at its subsidiary Fresenius Medical Care AG and a challenging macroeconomic situation.

Last week, the German healthcare company cut its guidance for the year after its 32%-owned subsidiary FMC said it would lower its outlook due to U.S. labor shortages and a worsening economic environment.

Fresenius's net income in the three months to the end of June fell 5% to 450 million euros ($461.8 million), though its sales climbed 8% to EUR10.02 billion.

Dialysis-care company FMC said its net income fell almost 40% to EUR147 million, while revenue rose 10% to EUR4.76 billion.

Fresenius Kabi, a drug-making subsidiary, had solid organic sales growth, while its Helios private-hospital operator continued good admissions growth at its German and Spanish markets, Fresenius said.

The Bad Homburg-based company confirmed its lowered guidance issued on July 27 of sales growth in a low-to-mid single-digit percentage range at constant currency, anticipating more pronounced headwinds in 2022 from supply-chain disruptions and cost inflation, including energy prices.

 

Write to Ed Frankl at edward.frankl@dowjones.com

 

(END) Dow Jones Newswires

August 02, 2022 01:44 ET (05:44 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Fresenius SE and Company... (PK) (USOTC:FSNUY)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024 Fresenius SE and Company... (PK) 차트를 더 보려면 여기를 클릭.
Fresenius SE and Company... (PK) (USOTC:FSNUY)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024 Fresenius SE and Company... (PK) 차트를 더 보려면 여기를 클릭.